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Roles for a lipid phosphatase in the activation 
of its opposing lipid kinase
ABSTRACT Fig4 is a phosphoinositide phosphatase that converts PI3,5P2 to PI3P. Paradoxi-
cally, mutation of Fig4 results in lower PI3,5P2, indicating that Fig4 is also required for PI3,5P2 
production. Fig4 promotes elevation of PI3,5P2, in part, through stabilization of a protein 
complex that includes its opposing lipid kinase, Fab1, and the scaffold protein Vac14. Here 
we show that multiple regions of Fig4 contribute to its roles in the elevation of PI3,5P2: its 
catalytic site, an N-terminal disease-related surface, and a C-terminal region. We show that 
mutation of the Fig4 catalytic site enhances the formation of the Fab1-Vac14-Fig4 complex, 
and reduces the ability to elevate PI3,5P2. This suggests that independent of its lipid phos-
phatase function, the active site plays a role in the Fab1-Vac14-Fig4 complex. We also show 
that the N-terminal disease-related surface contributes to the elevation of PI3,5P2 and pro-
motes Fig4 association with Vac14 in a manner that requires the Fig4 C-terminus. We find 
that the Fig4 C-terminus alone interacts with Vac14 in vivo and retains some functions of 
full-length Fig4. Thus, a subset of Fig4 functions are independent of its phosphatase domain 
and at least three regions of Fig4 play roles in the function of the Fab1-Vac14-Fig4 complex.
domains (Vicinanza et al., 2008; Waugh, 2015). Mutations in PI-PT-
Pases are associated with diseases including cancer and neurode-
generation (Liu and Bankaitis, 2010; Pulido et al., 2013; Billcliff and 
Lowe, 2014; Waugh, 2015). A common assumption is that patholo-
gies caused by mutations in PI-PTPases arise from failure to dephos-
phorylate lipid substrates. However, catalytically impaired mutants of 
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INTRODUCTION
Fig4, a Sac1-related phosphoinositide phosphatase (PI-PTPase), be-
longs to a diverse family of cysteine-dependent phosphatases that 
includes protein tyrosine phosphatases. These enzymes are highly 
divergent in sequence, but share an essential catalytic cysteine 
within a core CX5R catalytic motif (Alonso et al., 2016). PI-PTPases 
modulate signaling cascades in response to stimuli through localized 
dephosphorylation of phosphoinositide lipids on specific membrane 
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distinct from their null-mutations, which suggests that these enzymes 
possess functions independent of their lipid phosphatase activity 
(Amoasii et al., 2012; Krebs et al., 2013; Quadri et al., 2013; Dong 
et al., 2015; Bharadwaj et al., 2016; Lenk et al., 2016).
Fig4 is a phosphatidylinositol 3,5-bisphosphate (PI3,5P2) 5-phos-
phatase (Rudge et al., 2004) and is composed of an N-terminal 
Sac1-type phosphatase domain and a C-terminal domain specific to 
Fig4. Fig4 is proposed to be the primary enzyme responsible for the 
turnover of PI3,5P2 (Gary et al., 2002; Rudge et al., 2004; Duex 
et al., 2006a). Thus, loss of this enzyme is predicted to elevate levels 
of PI3,5P2. However, knockout of Fig4 paradoxically leads to lower 
levels of PI3,5P2 in yeast (Duex et al., 2006a) and mammals (Chow 
et al., 2007). Moreover, Fig4 has a positive role in the hyperosmotic 
shock–induced increase in PI3,5P2 (Duex et al., 2006a). Consistent 
with a conserved role for Fig4 in PI3,5P2 synthesis, the loss of Fig4 
results in enlarged lysosomes/vacuoles in yeast, flies, and mammals 
(Rudge et al., 2004; Duex et al., 2006b; Chow et al., 2007; Bharad-
waj et al., 2016), a phenotype associated with lower than normal 
levels of PI3,5P2 (Gary et al., 1998; Ikonomov et al., 2001; Rudge 
et al., 2004; Nicot et al., 2006). Notably, mutations in yeast Fig4 that 
correspond to human Fig4 mutations associated with Charcot–
Marie–Tooth syndrome Type 4J (CMT4J) and amyotrophic lateral 
sclerosis (ALS) result in defects in the stimulus-induced elevation of 
PI3,5P2 (Chow et al., 2007, 2009). These findings suggest that muta-
tions in Fig4 that underlie some neurological diseases impair Fig4-
dependent elevation of PI3,5P2.
Fig4 is proposed to enhance PI3,5P2 synthesis independent of 
its lipid phosphatase function through stabilization of the protein 
complex harboring Fab1/PIKfyve (Sbrissa et al., 2007, 2008; Botelho 
et al., 2008; Jin et al., 2008), the sole enzyme responsible for PI3,5P2 
production (Gary et al., 1998; Ikonomov et al., 2001; Nicot et al., 
2006; Rusten et al., 2006). This is supported by findings that catalyti-
cally impaired Fig4 rescues the enlarged lysosome phenotype ob-
served in Fig4 knockout flies (Bharadwaj et al., 2016) and partially 
restores osmotic shock–induced elevation of PI3,5P2 in yeast (Duex 
et al., 2006b). Catalytically impaired Fig4 also partially rescues neo-
natal abnormalities in Fig4 null mice (Lenk et al., 2016). The failure 
of catalytically impaired Fig4 to fully support elevation of PI3,5P2 
following hyperosmotic shock in yeast (Duex et al., 2006b) suggests 
that the Fig4 active site may contribute to Fab1 activation.
Here we show that formation of the yeast Fab1-Vac14-Fig4 com-
plex is modulated by at least three regions of Fig4: the Fig4 catalytic 
site, a conserved N-terminal surface mutated in some neurological 
diseases, and the C-terminus. Mutation of the catalytic cysteine of 
yeast or mammalian Fig4 enhances formation of the Fab1/PIKfyve-
Vac14-Fig4 complex in both yeast and human cells. In addition, we 
show that mutation of a disease-related N-terminal surface impairs 
the ability of Fig4 to interact with Vac14. Furthermore, we show that 
expression of the Fig4 C-terminus alone supports some in vivo func-
tions of Fig4 and that this region interacts with Vac14 in yeast ly-
sates. Moreover, the N-terminus promotes Fig4 association with 
Vac14 in a manner that also requires the Fig4 C-terminus. Together, 
the presence of three contact sites in Fig4 raises the possibility that 
the catalytic region in coordination with the N- and C-termini 
changes the conformation of Fig4, which in turn regulates the as-
sembly and/or activity of the Fab1-Vac14-Fig4 complex.
RESULTS AND DISCUSSION
The Fig4 phosphatase active site is required for full 
activation of Fab1
To investigate a potential role of Fig4 catalytic activity in Fab1 acti-
vation, we substituted the catalytic cysteine for serine (Fig4-C467S) 
to impair Fig4 catalytic function (Flint et al., 1997; Rohde et al., 
2003; Berger et al., 2006). Notably, Fig4-C467S displays a 33% de-
crease in the elevation of PI3,5P2 following hyperosmotic shock 
(Figure 1A). This suggests that the Fig4 catalytic cysteine is neces-
sary for the full activation of Fab1. As previously shown (Rudge 
et al., 2004), Fig4 functions as a lipid phosphatase. In further sup-
port of this hypothesis, expression of Fig4-C467S as the sole copy 
of Fig4 in a fig4Δ yeast strain resulted in a twofold elevation of basal 
PI3,5P2 levels relative to wild type (Fig4-WT) and an impaired rate of 
PI3,5P2 turnover following hyperosmotic shock (Figure 1A).
The Fig4-C467S mutant does not impair yeast viability, which 
indicates that some functions of Fig4 do not require catalytic activity. 
In a yeast strain where Vac14 and Fab1 are C-terminally tagged 
(fig4Δ Vac14-Venus Fab1-TAP), Fig4 expression is required for 
growth at temperatures higher than 30°C. Using this strain, we find 
that expression of Fig4-C467S supports growth similarly to WT 
(Figure 1B). This fits with studies in mice (Lenk et al., 2016) and 
Drosophila (Bharadwaj et al., 2016), where catalytically impaired 
Fig4 partially rescues Fig4 knockout mutants.The Fig4 active site 
modulates its association with Fab1.
The defect in Fab1 activation due to mutation of the Fig4 cata-
lytic cysteine could result from partial misfolding and impaired as-
sociation with the Fab1-Vac14-Fig4 complex. To test this possibility, 
we performed pull-down experiments of Fig4 in yeast expressing 
Fig4-WT versus Fig4-C467S. Fig4-C467S is expressed at levels simi-
lar to those in wild-type Fig4, yet strikingly, the Fig4-C467S mutant 
resulted in an ∼14-fold increase in Fab1 association with Fig4 
(Figure 1C). Two other catalytically impaired mutants, Fig4-D469A 
and Fig4-Y538A, do not show the same degree of enhanced bind-
ing (Supplemental Figure S1, A–D). This implies that enhanced as-
sociation of Fig4-C467S with Fab1 is not a consequence of loss of 
Fig4 catalytic function but is directly mediated by contacts with the 
mutant Fig4-C467S active site. Association with Fab1 is not a result 
of altered localization of Fig4-C467S in yeast cells, as Fig4-C467S-
Envy and Fig4-Y538A-Envy show similar localization (Supplemental 
Figure S1E). Moreover, Fab1-3xGFP shows similar localization in the 
presence of Fig4-WT, -C467S, or -Y538A (Supplemental Figure S1F). 
Some, but not all, mutations of catalytic residues in protein phos-
phatases lead to enhanced binding to their protein substrates (Flint 
et al., 1997; Blanchetot et al., 2005). It is possible that enhanced 
binding of Fig4 to Fab1 reflects protein targets of Fig4 phosphatase 
function within the Fab1-Vac14-Fig4 complex. Alternatively the Fig4 
active site may modulate conformational rearrangements in the 
Fab1/PIKfyve-Vac14-Fig4 complex that alter Fab1 binding. Notably, 
enhanced binding of Fig4-C467S to Fab1 requires prior assembly of 
the Fab1-Vac14-Fig4 complex as binding of this mutant to Fab1 is 
not detected in the absence of Vac14 (Supplemental Figure S2). The 
mechanism of enhanced association of the Fig4-C467S mutant with 
Fab1 is likely conserved. In HEK293T cells that overexpress human 
Fig4 with a mutated catalytic cysteine, Fig4-C486S, we observed an 
approximately ninefold increase in association with the mammalian 
Fab1 homologue, PIKfyve (Figure 1D).
A conserved, disease-related N-terminal surface of the Fig4 
phosphatase domain modulates its association with Fab1 
and Vac14
In addition to the catalytic site, we investigated the role of a con-
served, disease-related surface of Fig4. Previous studies raised the 
possibility that this region may be critical to Fig4 function. The 
CMT4J disease mutation I49T (I59T in yeast) (Chow et al., 2007) is 
predicted to be buried within the Fig4 N-terminus (Manford et al., 
2010; Lenk et al., 2011; Figure 2A). This mutation disrupts association 
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of human Fig4 with human Vac14. In addition, yeast Fig4-I59T ex-
hibits impaired interactions with yeast Vac14, as measured in yeast 
two-hybrid assays as well as in pull-down assays (Lenk et al., 2011). 
Importantly, yeast Fig4-I59T results in a >50% defect in elevation of 
PI3,5P2 following hyperosmotic shock (Chow et al., 2007). However, 
because the Fig4-I59T mutation is likely a buried residue, it is diffi-
cult to conclude whether the associated defects are due to overall 
misfolding of the protein, or whether they are due to some specific 
function of the nearby N-terminal surface.
We hypothesized that the ALS-related mutations D48G or D53Y 
and surrounding surface area would likely provide a better means to 
study the functional significance of the N-terminal surface. These 
mutations are on a predicted surface in close proximity to I49 
(Manford et al., 2010; Cai et al., 2014). Mutation of the correspond-
ing residues in yeast, E67G and E72Y, results in enlarged vacuole 
morphology, suggesting that these mutations are impaired in the 
activation of Fab1 (Chow et al., 2009).
Notably, using a structural model of Fig4 (Manford et al., 
2010, and Figure 2A), we found that this N-terminal surface of 
Fig4 is highly conserved in Fig4 proteins from diverse species 
(Figure 2B). This surface includes several negatively charged resi-
dues, including E51 and the residues corresponding to the ALS 
FIGURE 1: Catalytically impaired Fig4 supports partial Fig4 function. (A) PI3,5P2 was analyzed by HPLC from fig4Δ cells 
labeled with [3H]inositol. NaCl (0.9 M) was added to the media at 0 time. The hyperosmotic shock–induced rise in 
PI3,5P2 (10 min levels minus basal levels) is decreased by 33 ± 1% in Fig4-C467S compared with Fig4-WT (p = 0.0022, 
two-tailed t test). Basal levels of PI3,5P2 are 2.1± 0.4-fold higher in Fig4-C467S relative to wild type (p = 0.0082, 
two-tailed t test). Mean of four independent experiments. Error bars: SD. (B) Catalytically impaired Fig4 substitutes for 
wild-type Fig4 to support growth at 37°C in a fig4Δ Vac14-Venus Fab1-TAP strain. Cells expressing no Fig4, Fig4-wild-
type (WT), or catalytically impaired Fig4 (C467S) from a plasmid were grown on selective SC–leu plates at 24° and 37°C. 
(C) Western blot of proteins immunoprecipitated with anti-Myc antibody from a fig4Δ strain expressing Fig4-4xMyc 
wild-type (WT-Myc), C467S (CS-Myc), or untagged Fig4 wild-type (WT-tagless) from a plasmid with native 5′ and 3′ UTR. 
Vac14-Venus and Fab1-6xHA expressed from endogenous loci. (D) Western blot of proteins immunoprecipitated with 
anti-Citrine antibody from HEK293T cells transfected with Fig4-Citrine, Fig4-C486S-Citrine, or Citrine alone. Bar graphs 
show quantification of Western blots in C and D. In yeast, Fab1 association with Fig4 C467S is 14.06 ± 2.81 times higher 
than wild-type Fig4, normalized to Fig4. Data points and mean of three independent experiments (** p = 0.0006, 
two-tailed t test). In HEK293T cells, PIKfyve association with Fig4 C486S is 9.27 ± 4.75-fold higher relative to wild-type 
Fig4. Data points and mean from two independent experiments.
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FIGURE 2: A conserved N-terminal surface of Fig4 is required for the activation of Fab1 and for Fig4 binding to Fab1 
and Vac14. (A, B) Predicted structure of the Fig4 phosphatase domain (amino acids 32–529) using Phyre2 (Kelley et al., 
2015), based on homology with Sac1 (Manford et al., 2010). (A) Cartoon representation of the N-terminal lobe (blue) 
and catalytic region (gray) of the Fig4 phosphatase domain. ALS and CMT4J mutations (cyan) and the catalytic cysteine 
(red) are shown as sticks. I59 corresponds to human CMT4J mutation I41T. E67 and E72 correspond to ALS mutations 
D48G and D53Y, respectively. (B) Surface representation of a top-down view of the predicted Fig4 N-terminal surface. 
(C, D) PI3,5P2 was analyzed by HPLC from cells labeled with [3H]inositol. NaCl (0.9 M) was added to the media at 0 time. 
(C) Mean of three independent experiments. The 10 min level decreased relative to WT in E51K (p = 0.0008, two-tailed t 
test) and T52AE51KE72K (p = 0.0003, two-tailed t test). The change was not statistically significant for E72K (p = 0.0986, 
two-tailed t test). (D) Mean of two independent experiments with individual data points shown. (E) Growth defects in 
Fig4 mutants in fig4Δ Vac14-Venus Fab1-TAP at 37°C correlate with corresponding defects in elevation of PI3,5P2. Cells 
expressing no Fig4, Fig4-wild-type (WT), or indicated Fig4 mutants from a plasmid were grown on selective Sc–leu 
Volume 31 August 1, 2020 PI phosphatase-independent roles of Fig4 | 1839 
mutations, E67 and E72. This surface also harbors three highly 
conserved threonines, T52, T62, and T78 (Figure 2B). Charge re-
versal mutations of acidic residues and alanine mutations of the 
threonines, singly or in combination (Figure 2, C and D), did not 
display significant defects in PI3,5P2 turnover, but resulted in par-
tial defects in the elevation of PI3,5P2 following hyperosmotic 
shock. The triple mutants FIG4-E51KT52AE72K and FIG4-
T52AT62AT78A have large defects in PI3,5P2 synthesis and turn-
over and phenocopy the defects in PI3,5P2 levels observed in a 
fig4Δ mutant, which suggests that this region is critical to forma-
tion of the Fab1-Vac14-Fig4 complex. Consistent with the impor-
tance of acidic residues on this surface, mutation of one of the 
threonines to glutamate (T52E) slightly enhanced Fab1 activation 
following hyperosmotic shock (Figure 2D). In addition, growth 
defects imparted by the disease-related mutations correlate with 
corresponding defects in PI3,5P2 elevation. FIG4-E72Y and FIG4-
I59T result in a minor growth defect relative to WT at 37°C. In 
addition, whereas FIG4-T52ET62ET78E displays a minor growth 
defect, FIG4-T52AT62AT78A has a severe growth defect (Figure 
2E). These data further support the hypothesis that the N-termi-
nal surface of Fig4 plays a role in the activation of Fab1.
To test whether these conserved threonines on the N-terminal 
surface of Fig4 are regulated by phosphorylation, we performed 
affinity purification of FLAG-tagged Fig4 and subjected tryptic di-
gests of copurified proteins to phosphopeptide enrichment by im-
mobilized metal affinity chromatography. We did not detect phos-
phopeptides derived from the N-terminal domain of Fig4, despite 
the fact that many peptides from Fig4 were resolved (56% coverage 
of the total protein), including unmodified peptides covering T62 
and T78 (Supplemental Table 1). This analysis does not rule out 
N-terminal regulation by phosphorylation—particularly at residues 
that could not be resolved by tryptic digest such as T52.
To test whether this N-terminal surface mediates binding of Fig4 
to the Fab1-Vac14-Fig4 complex, we performed immunoprecipita-
tion assays with a subset of the Fig4 point mutants (Figure 2F). The 
mutants were stably expressed. The triple mutant FIG4-
T52AT62AT78A was severely impaired in its association with Vac14 
and Fab1. The triple mutant FIG4-T52ET62ET78E was also partially 
deleterious to Fig4 association with Vac14 and Fab1. Together, 
these data indicate that the N-terminal surface of Fig4 is critical for 
the integrity of the Fab1-Vac14-Fig4 complex.
The Fig4 C-terminus mediates contact of the N-terminal 
phosphatase domain with the Fab1-Vac14-Fig4 complex
Fig4 is composed of two primary regions (Figure 3A), its N-terminal 
Sac1 phosphatase domain, which includes the catalytic site, and a 
C-terminal region specific to Fig4. To test the contributions of these 
domains to PI3,5P2 elevation independent of each other, we ex-
pressed Fig4 as two separate peptides: the N-terminal phosphatase 
domain (Fig4-Nterm, a.a. 1–577) and the C-terminus (Fig4-Cterm, 
a.a. 577–end[879]) (Figure 3B) and tested their ability to support 
Fig4-dependent growth. We found that the Fig4 C-terminus alone, 
but not the Fig4 N-terminus, partially restored growth. When coex-
pressed, the Fig4 N-terminus and Fig4 C-terminus complemented 
growth comparably to full-length Fig4 (Figure 3C). Together, these 
data indicate that the C-terminus of Fig4 retains some critical func-
tions of the full-length protein, further supporting assertions that 
some Fig4 functions are entirely independent of its catalytic activity. 
Moreover, that the Fig4 N-terminus and Fig4 C-terminus support 
growth when expressed as separate polypeptides enabled us to 
perform further experiments to test the independent roles of these 
domains.
Fig4 binds Vac14 (Botelho et al., 2008; Ikonomov et al., 2009), 
and immunoprecipation studies with mammalian Fig4 and genetic 
analysis in yeast suggested that this interaction occurs through the 
Fig4 C-terminus (Botelho et al., 2008; Ikonomov et al., 2009). By 
immunoprecipitation, we found that the yeast Fig4 C-terminus 
binds Vac14 (Figure 3D). However, much less Vac14 is immunopre-
cipitated than is observed with full-length Fig4. On the basis of 
the observation that mutation of residues on the N-terminal sur-
face disrupts Fig4 association with Vac14 (Figure 2F), we tested 
whether expression of the Fig4 N-terminal domain alone could 
pull down Vac14, but found that it could not (Figure 3E). However, 
when the Fig4 N-terminus and C-terminus were coexpressed, 
pulling down on the Fig4 N-terminus coprecipitated Vac14 (Figure 
3E). These data suggest that when expressed as separate poly-
peptides, the Fig4 N-terminus interacts with either Vac14, Fab1 
and/or the Fig4 C-terminus. Note that Fab1 is present in the yeast 
strains used in these pull-down studies and could be playing a role 
in the association of the Fig4 N-terminus with the C-terminus. 
They also suggest that, while the C-terminus is necessary and suf-
ficient for Vac14 binding, in the context of full-length Fig4 the N-
terminus contributes to binding interactions with the Fab1-Vac14-
Fig4 complex.
The Fig4 C-terminus interacts with the N-terminal 
phosphatase domain
To determine whether the Fig4 N-terminus binds the Fig4 C-termi-
nus, we tested whether these regions stably interact in the absence 
of Vac14. Indeed, when expressed in fig4Δvac14Δ yeast, the Fig4 
N-terminus coimmunoprecipitated with the Fig4 C-terminus (Figure 
4A). Moreover, the N-terminal constructs mutated on the disease 
surface, T52AT62AT78A or T52ET62ET78E, retain the ability to bind 
the Fig4 C-terminus (Figure 4A).
To further test the mutations on the surface of the Fig4 N-termi-
nus, we tested the ability of the T52AT62AT78A or T52ET62ET78E 
mutants to support yeast growth when coexpressed with the Fig4 
C-terminus. However, we found that only the wild-type Fig4 N-ter-
minus when coexpressed with the Fig4 C-terminus supported 
growth to the same extent as full-length wild-type Fig4 (Figure 4B). 
The Fig4 N-terminus with surface mutations made no further contri-
bution to the ability of the Fig4 C-terminus alone to support yeast 
growth. This result was somewhat surprising given that full-length 
Fig4-T52ET62ET78E supported growth to the same extent as Fig4 
wild type (Figure 2E). Thus, in the next study of the N-terminal 
surface, we utilized full-length Fig4.
plates at 24° and 37°C. (F) Western blot of proteins immunoprecipitated with anti-Myc antibody from a fig4Δ strain 
expressing Fig4-4xMyc from a plasmid with native 5′ and 3′ UTR, and Vac14-Venus and Fab1-6xHA expressed from their 
corresponding endogenous loci. Bar graph shows quantification of band densities in Western blot, relative to wild type, 
normalized to Fig4-Myc, with data points and mean from three independent experiments (* p < 0.01, *** p < 0.0001, by 
two-tailed t test). Fig4 mutants analyzed: E72K, E72Y, E51K, triple mutant T52AE51KE72K, T52E, T52A, double mutant 
T52AT62A, triple mutant T52ET62ET72E (EEE), and triple mutant T52AT62AT72A (AAA).
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FIGURE 3: Synergistic function of the Fig4 C- and N-termini depends on association of the Fig4 C-terminus with Vac14. 
(A) Linear representation of the Fig4 primary sequence. (B) N-terminal HA-tagged Fig4 phosphatase domain (Fig4-
NTerm) (amino acids 1–577) and 4xMyc-tagged Fig4 C-terminal tail (Fig4-CTerm) (amino acids 577–879). (C) The 
Fig4-Cterm, but not the Fig4-Nterm, supports partial growth in fig4Δ Vac14-Venus Fab1-TAP at 33°C. The Fig4 Nterm 
contributes to and complements full Fig4 function only in the presence of the Fig4-Cterm. Cells expressing no Fig4, 
Fig4-wild-type (WT), or overexpressing the indicated Nterm and Cterm constructs from plasmids were grown on 
selective Sc–his–leu plates at 24° and 33°C. (D, E) Western blot of proteins immunoprecipitated with anti-Myc antibody 
(D) or anti-HA beads (E) from a fig4Δ strain expressing Vac14-Venus from its endogenous locus and expressing either no 
Fig4, Fig4-4xMyc from a plasmid with native 5′ and 3′ UTR, or overexpression (via an ADH promoter) of Fig4-Nterm 
and/or Fig4-CTerm. Bar graph shows quantification of band densities in Western blot (D) relative to full-length Fig4, 
normalized to Fig4-Myc, with data points and mean from two independent experiments and (E) relative to Nterm-
WT+Cterm, normalized to NTerm, with data points and mean from three independent experiments (*** p < 0.0001, 
by two-tailed t test).
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The Fig4 N-terminal surface contributes to stable binding 
of Fig4 to Vac14
Fig4 binds Vac14 independent of Fab1 (Botelho et al., 2008; 
Ikonomov et al., 2009). To test whether the disease-related surface 
of Fig4 contributes to its binding to Vac14, we used immunopre-
cipitation assays and tested the ability of full-length Fig4 bearing 
N-terminal surface mutations to bind Vac14 in the absence of 
Fab1. Threonine to alanine mutations, FIG4-T52AT62AT78A, on the 
N-terminal disease-related surface impaired binding to Vac14 
(Figure 4C). Mutation of these threonines to glutamate, FIG4-
T52ET62ET78E, impaired binding to a lesser extent. These data 
suggest that, in the context of full-length Fig4, the disease-related 
FIGURE 4: The Fig4 N-terminal and C-terminal domains mediate Fab1-Vac14-Fig4 complex assembly and function 
through contacts on Vac14. (A) Western blot of proteins immunoprecipitated with anti-Myc antibody from a fig4Δvac14Δ 
strain overexpressing the Fig4 C-terminus (CTerm-4xMyc) and/or the wild-type (WT), C467S (CS), T52AT62AT78A (AAA), 
or T52ET62ET78E (EEE) Fig4 phosphatase domain (HA-N-term) via an ADH promoter. Bar graph shows quantification of 
band densities in Western blot, relative to wild type, normalized to Cterm-Myc with data points and mean from two 
independent experiments. (B) In contrast to wild type, Fig4-Nterm AAA and Nterm-EEE do not support growth in the 
presence of the Fig4-Cterm in fig4Δ Vac14-Venus Fab1-TAP at 33°C. Cells expressing no Fig4, Fig4-wild-type (WT), or 
overexpressing the indicated Nterm and Cterm constructs from plasmids were grown on selective Sc–his–leu plates at 
24° and 33°C. (C) Western blot of proteins immunoprecipitated with anti-Myc antibody from a fig4Δfab1Δ expressing 
Fig4-WT, Fig4-CS, Fig4-AAA, or Fig4-EEE. Vac14-Venus expressed from endogenous locus. Bar graph shows 
quantification of band densities in Western blot, relative to wild type, normalized to Fig4-Myc, with data points and 
mean from three independent experiments (*** p < 0.0001, ** p < 0.001, two-tailed t test). (D) Model for regulation of 
the Fab1-Vac14-Fig4 complex. The Fig4 C-terminus and an N-terminal surface (star) both contribute to its association 
with Vac14 within the Fab1-Vac14-Fig4 complex. The Fig4 catalytic site is also required for the full activation of Fab1.
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N-terminal surface contributes to the interaction of Fig4 with Vac14. 
It is also possible that this surface contacts an as yet unidentified 
subunit in the complex.
Model for dynamic regulation of Fab1 by Fig4
Together, our data suggest a model (Figure 4D) whereby Fig4 con-
tributes to the function of the Fab1-Vac14-Fig4 complex through 
both active site–dependent and active site–independent mecha-
nisms. We show that three regions of Fig4 mediate the association 
and function of the Fab1-Vac14-Fig4 complex: the active site, an 
N-terminal disease-related surface, and the C-terminus. We find 
that the Fig4 active site influences the stability and function of the 
complex. Our data also suggest that Fig4 stabilizes the Fab1-Vac14-
Fig4 complex through two contacts with Vac14, the disease-related 
Strain/plasmid Genotype/description Source
LWY6474 MATa, leu2, 3-112, ura3-52, his3-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1
Duex et al., 2006b
LWY6538 MATα, leu2,3-112, ura3-52, his-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1, vac14Δ::TRP1
Duex et al., 2006b
LWY8640 MATa, leu2,3-112, ura3-52, his-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1, VAC14-Venus::KAN
Jin et al., 2008
LWY8812 MATa, leu2,3-112, ura3-52, his-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1, FAB1-3XGFP::KAN
Jin et al., 2008
LWY14459 MATa, leu2,3-112, ura3-52, his-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1, VAC14-Venus::KAN, FAB1-TAP::KAN
This study
LWY15782 MATa, leu2,3-112, ura3-52, his-Δ200, trp1-Δ901, lys2-801, suc2-Δ9, 
fig4Δ::TRP1, VAC14-Venus::KAN, FAB1-6xHA::NAT
This study
pRS415-Fig4 Yeast centromere plasmid; LEU2 Jin et al., 2008
pRS415-Fig4-C467S Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-Y538A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-E72K Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-E51K Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-E51KT52AE72K Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T52A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T62A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T78A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T52AT62A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T52AT62AT78A Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T52E Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-T52ET62ET78E Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-4xMyc Yeast centromere plasmid; LEU2 Jin et al., 2008
pRS415-Fig4-4xMyc-C467S Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-4xMyc-EEE Yeast centromere plasmid; LEU2 This study
pRS415-Fig4-4xMyc-AAA Yeast centromere plasmid; LEU2 This study
pRS415ADH Yeast centromere plasmid; LEU2 Mumberg et al., 1995
pRS415ADH-Fig4-CTerm Yeast centromere plasmid; LEU2 This study
pRS413ADH Yeast centromere plasmid; HIS3 Mumberg et al., 1995
pRS413ADH-Fig4-NTerm Yeast centromere plasmid; HIS3 This study
pRS413ADH-Fig4-NTerm-C467S Yeast centromere plasmid; HIS3 This study
pRS413ADH-Fig4-NTerm-EEE Yeast centromere plasmid; HIS3 This study
pRS413ADH-Fig4-NTerm-AAA Yeast centromere plasmid; HIS3 This study
pRS413-Fig4-Envy Yeast centromere plasmid; HIS3 This study
pRS413-Fig4-Envy-C467S Yeast centromere plasmid; HIS3 This study
pRS413-Fig4-Envy-Y538A Yeast centromere plasmid; HIS3 This study
pRS416 Fab1-3xGFP Yeast centromere plasmid; URA3 Jin et al., 2008
TABLE 1: Strains and plasmids used in this study.
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N-terminal surface on Fig4 and the Fig4 C-terminus. Interactions 
involving the N-terminus are enhanced by mutation of the catalytic 
cysteine to serine (Figures 3E and 4A), suggesting that the active 
site also directly contacts the complex. Given that the Fig4 active 
site resides between two distal contact sites on Fig4, it is tempting 
to speculate that conformational changes that originate in the active 
site could impact the conformation of the Fab1-Vac14-Fig4 com-
plex via their interactions with the Fig4 N-terminal disease-related 
surface and the C-terminus. These putative conformational changes 
may underlie the activation of Fab1 by Fig4.
There are several other examples of cysteine-dependent PI-PT-
Pases that have both active site–dependent and –independent 
roles. In mice, catalytically dead mutants of the PI-PTPase Mtm1 
partially rescue phenotypes caused by absence of the wild-type pro-
tein (Amoasii et al., 2012; Lenk et al., 2016). Moreover, the wild-type 
alleles of a number of physiologically important PI-PTPase–related 
enzymes, including almost half of the myotubularin family (Robinson 
and Dixon, 2006) as well as 10% of all cysteine-dependent protein 
tyrosine phosphatases, are predicted to be catalytically inactive be-
cause they lack the amino acids essential for phosphatase function 
in their otherwise conserved catalytic motifs (Moorhead et al., 2009).
PI-PTPases are activated and inactivated in response to specific 
stimuli (Yu and Zhang, 2018). Conformational changes associated 
with activation and inactivation have been demonstrated for PTEN 
(Raftopoulou et al., 2004; Odriozola et al., 2007; Rahdar et al., 2009; 
Bolduc et al., 2013; Masson et al., 2016) and are predicted for Sac1 
(Manford et al., 2010; Zhong et al., 2012) and Mtm1 (Schaletzky 
et al., 2003). Moreover, catalytically impaired mutants have been 
shown to display altered noncatalytic behavior relative to the wild-
type enzyme. For instance, inactive PTEN causes dominant negative 
phenotypes; mice bearing one wild-type and one phosphatase 
dead allele are more prone to tumor development than mice that 
have one wild-type and one null PTEN allele (Papa et al., 2014). In 
addition, Sac1 (Rohde et al., 2003; Papa et al., 2014; Yu et al., 2014; 
Dong et al., 2015) displays altered protein–protein interactions. 
Similarly, we find that the Fig4-C467S mutant exhibits an enhanced 
interaction with Fab1. Conformational changes within PI-PTPases 
may have the potential to influence physically associated proteins, 
analogous to regulatory GTPases (Clague et al., 2004). Together, 
these studies along with previously published findings reveal that 
PI-PTPases perform critical cellular functions that are independent 
of their catalytic activity, of which a subset likely involve conforma-
tional changes that are mediated via the PI-PTPase active site.
MATERIALS AND METHODS
Yeast strains and plasmids
Strains and plasmids used in this study are listed in Table 1. Yeast 
were grown in yeast extract–peptone–dextrose (1% yeast extract, 
2% peptone, 2% dextrose; YEPD) or synthetic complete (SC) mini-
mal medium without selective amino acids at 24°C. SC medium 
contained 2% dextrose. For plate assays, a fig4Δ Vac14-Venus Fab1-
TAP yeast strain was transformed with plasmids expressing full-
length Fig4 or Fig4 Nterm and Cterm. Transformed cells were 
grown overnight in Sc-Leu media (full-length Fig4) or Sc-His-Leu 
media (Fig4 Nterm and Cterm) to mid–log phase. Cultures were di-
luted to ∼5 × 106 cells per ml and 10 μl of a 10-fold serial dilution was 
plated on Sc-His or Sc-His-Leu plates and grown at 24° and 33°C for 
3 d or 37°C for 2 d.
Phosphoinositide lipid labeling and quantification
Yeast [3H]inositol labeling and total cellular phosphatidylinositol 
extraction, deacylation, and measurements were performed as 
previously described (Bonangelino et al., 2002; Duex et al., 2006a). 
fig4Δ yeast with plasmids expressing wild-type Fig4 or Fig4-C467S 
from the native Fig4 5′ and 3′ UTR (or no Fig4) were labeled with [3H]
inositol and treated with 0.9 M NaCl at 0 time. Cells were grown in 
the appropriate SC medium to an OD600 of 0.5. Cells (0.2 OD600 
U) were washed with SC medium lacking inositol and used to inocu-
late 5 ml of medium lacking inositol and containing 50 μCi of myo-
[3H]inositol. Cells were labeled 16 h with shaking at 24°C, harvested 
by centrifugation, and resuspended in 100 μl of inositol-free me-
dium. For hyperosmotic shock, 100 μl of inositol-free medium with 
1.8 M NaCl was added to the 100 μl of sample and then stopped via 
the addition of 800 μl ice-cold 4.5% perchloric acid. For basal condi-
tions, 100 μl of inositol-free medium was added, followed by the 
addition of ice-cold 4.5% perchloric acid. Cells were lysed on a 
Beadbeater (Biospec) for 2 min at room temperature, followed by 
resting 2 min on ice. This was performed three times. Cell extracts 
were centrifuged at 14,000 rpm for 15 min at room temperature. 
Pellets were washed with 100 mM EDTA, pH 8.0, and resuspended 
in 50 μl of distilled deionized water. The lipids were deacylated by 
treatment with methylamine. Samples were dried in a SpeedVac. 
Pellets were resuspended in 300 μl of distilled deionized water. The 
samples were then mixed with 300 μl of butanol/ethyl ether/formic 
acid ethyl ester (20:4:1), vortexed, and centrifuged at 14,000 rpm for 
5 min. The aqueous phase was transferred to a fresh microcentrifuge 
tube. This sample extraction was performed twice. Samples were 
then dried on a SpeedVac, resuspended in 60 μl of distilled deion-
ized water, and analyzed by high-performance liquid chromatogra-
phy (HPLC) using an anion exchange, PartisphereSAX (Whatman), 
column, as previously described (Bonangelino et al., 2002).To com-
pare phosphatidylinositol polyphosphate (PI) levels, the raw counts 
in each peak were expressed as a percentage of total phosphati-
dylinositol calculated from summation of the counts of the five glyc-
erol-inositol phosphate peaks (PI, PI3P, PI4P, PI3,5P2, and PI4,5P2).
Immunoprecipitations from yeast
fig4Δ yeast strains (fig4ΔVac14-Venus, fig4ΔVac14-VenusFab1-
6xHA, or fig4Δvac14Δ) were transformed with plasmids expressing 
4xMyc-tagged or HA-tagged Fig4 or empty vector. Log-phase cells 
(25 OD600 U) were harvested and lysed in immunoprecipitation (IP) 
buffer (50 mM Tris, pH 7.5, 120 mM NaCl, 10 mM EDTA, 1 mM eth-
ylene glycol tetraacetic acid [EGTA], 5 mM 2-glycerophosphate, 1 × 
Roche Complete inhibitor cocktail, and 1x Sigma Protease Inhibitor 
Cocktail) for use with fungal and yeast extracts supplemented 
with 3 mM benzamidine, 3 μg/ml leupeptin, 5 μg/ml aprotonin, and 
18 μg/ml chymostatin. All steps were carried out at 4°C. Debris was 
removed by centrifugation for 5 min at 500 × g. The supernatant was 
mixed with 5% octyl-glucoside (Sigma) in lysis buffer for a final con-
centration of 0.5% octyl-glucoside and incubated for 30 min. Octyl-
glucoside–solubilized lysate was cleared by spinning at 13,000 × g 
for 10 min. For Fig4-4xMyc and Vac14-Venus or Fab1-GFP pull 
downs, 1 μl per 100 μl lysate mouse anti-Myc (9E10; Fisher) or mouse 
anti-GFP (Roche) was added, respectively. Supernatants were incu-
bated with antibodies 1 h, and then ∼100 μl lysate was applied to 
10 μl equilibrated Protein-G Sepharose beads (Sigma) or SureBeads 
Protein-G magnetic beads (Bio-Rad) and incubated with rocking for 
1 h. For HA-Fig4 pull downs, supernatants were incubated with rock-
ing for 1 h with 20 μl of goat anti-HA agarose beads (Bethel). Pro-
tein-G or anti-HA beads were washed three times with 500 μl of IP 
buffer containing 0.5% octyl-glucoside. Bound protein was eluted 
by heating immunoglobulin G beads with 25 μl of sample buffer (1% 
SDS, 8 M urea, 10 mM Tris, pH 6.8, 10 mM EDTA, 0.01% bromophe-
nol blue) at 75°C for 10 min. SDS–PAGE and Western blot analysis 
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were used to detect Fab1-6xHA, HA-Fig4 fragments (rabbit anti-HA; 
Cell Signalling), Fig4-4xMyc full-length and fragments (rabbit anti-
Myc; Cell Signalling), and Vac14-Venus (mouse anti-GFP-Roche). 
Western blots were quantified using ImageJ. Fab1 bands normal-
ized to Fig4 in corresponding pull down.
Immunoprecipitations from HEK293T cells
Each 10 cm dish of HEK293T cells was transfected with 8 μg of the 
indicated pCMV-based plasmid, Fig4-Citrine Wild-type, Fig4-C486S-
Citrine, or Citrine alone using lipofectamine 2000 (Invitrogen). Forty-
two hours posttransfection, cells were lysed on ice in 500 μl binding 
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM MgCl2, and 1x 
Roche EDTA free Complete protease inhibitors) with 1% Brij. All 
subsequent steps were performed at 4°C. Lysates were cleared by 
centrifugation for 15 min at 13,000 rpm and supernatants were ap-
plied to 20 μl protein-G agarose beads (Sigma) prebound with 1 μl 
anti-GFP antibody in 100 μl lysis buffer and incubated with rocking 
for 2 h. Beads were washed three times with 1 ml binding buffer with 
0.1% Brij and eluted with 30 μl sample buffer (see Immunoprecipita-
tions from yeast) at 80°C for 5 min. SDS–PAGE and Western blot 
analysis were used to detect Fig4-Citrine (mouse anti-GFP; Roche) 
and endogenous PIKfyve (anti-PIKfyve antibody clone R159.4.3C9; 
Developmental Studies Hybridoma Bank, University of Iowa). West-
ern blots quantified using ImageJ. Pikfyve bands normalized to Fig4 
in corresponding pull down.
Fluorescence microscopy
Yeast were grown in the appropriate SC medium to an OD600 of 0.5 
and then were labeled with FM4-64 (Vida and Emr, 1995). Images 
were acquired using the DeltaVision RT Restoration Microscopy Sys-
tem (Applied Precision, Issaquah, WA).
Mass spectrometry analysis of Fig4
Cells expressing Fig4-FLAG were grown to mid–log phase (OD600 
∼ 0.7), and affinity purification was performed as previously de-
scribed (MacGurn et al., 2011; Lee et al., 2017). Briefly, cells were 
pelleted, washed with Tris-EDTA, pH 8.0, and frozen as dry 
pellets. Cell lysates were prepared by bead beating in lysis buffer 
(50 mM Tris, 0.2% NP-40, 150 mM NaCl, 5 mM EDTA, 2X Complete 
EDTA-Free protease inhibitor tablets, 1X PhosStop). M2 flag 
beads (Sigma) were added to the lysates and rotated for 2 h at 
4°C. The beads were washed and then eluted in elution buffer 
(100 mM Tris, 1% SDS) at 95°C for 5 min. Eluates were reduced by 
addition of 10 mM dithiothreitol and then alkylated by addition of 
20 mM iodoacetimide. Samples were then precipitated, resus-
pended (50 mM Tris, 8 M urea), and digested with 1 μg of trypsin 
overnight at 37°C. Phosphopeptide enrichment by immobilized 
metal affinity chromatography was performed as previously de-
scribed (Albuquerque et al., 2008). Peptide samples were dried, 
reconstituted in 0.1% trifluoroacetic acid, and analyzed by liquid 
chromatography with tandem mass spectrometry using an 
Orbitrap XL mass spectrometer. Raw data were analyzed using 
MaxQuant software.
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